Puxitatug Samrotecan + Doxorubicin + Paclitaxel
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer, Malignant Solid Tumour
Trial Timeline
Aug 1, 2025 → Jul 17, 2029
NCT ID
NCT07044336About Puxitatug Samrotecan + Doxorubicin + Paclitaxel
Puxitatug Samrotecan + Doxorubicin + Paclitaxel is a phase 3 stage product being developed by AstraZeneca for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07044336. Target conditions include Endometrial Cancer, Malignant Solid Tumour.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07044336 | Phase 3 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer